BioNTech SE Cash Flow Reinvestment Rate
BioNTech SE cash flow reinvestment rate. BioNTech SE (22UA) has a Cash Flow Reinvestment Rate of 9.66x as of December 2025, reinvesting €2.99 Billion (capex €62.10 Million plus investments €-2.93 Billion) from operating cash flow of €309.50 Million. Explore BioNTech SE cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of BioNTech SE (2021–2025)
Cash flow reinvestment rate of BioNTech SE from 2021 to 2025. Historical reinvestment intensity for BioNTech SE across 5 annual periods. Explore 22UA capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
BioNTech SE Cash Flow Reinvestment Rate by Year (2021–2025)
BioNTech SE cash flow reinvestment rate by year from 2021 to 2025. Year-by-year capital reinvestment analysis for BioNTech SE. For the full cash flow conversion analysis, see 22UA cash flow metrics.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 5.83x | €2.66 Billion | €456.00 Million | €749.00 Million | ▼ -41.8% |
| 2024 | 10.03x | €2.08 Billion | €207.70 Million | €452.30 Million | ▲ +713.8% |
| 2023 | 1.23x | €6.62 Billion | €5.37 Billion | €705.50 Million | ▲ +4096.5% |
| 2022 | 0.03x | €398.60 Million | €13.58 Billion | €363.30 Million | ▼ -95.0% |
| 2021 | 0.59x | €522.20 Million | €889.70 Million | €127.50 Million | — |